Restricted accessResearch articleFirst published online 2020-06
High Levels of Apoptosis Are Induced in the Human Colon Cancer HT-29 Cell Line by Co-Administration of Sulforaphane and a Peptide Nucleic Acid Targeting miR-15b-5p
Sulforaphane (SFN) is one of most important dietary constituents of broccoli (Brassica oleracea) and other cruciferous vegetables, which have been reported to exhibit health benefits, including prevention and therapy of cancer, such as colorectal carcinoma (CRC). The objective of this study was to determine whether the anticancer effect of SFN on colon cancer HT-29 cell line could be improved by the combined treatment with molecules inhibiting microRNAs (miRNAs) involved in CRC. As miRNA inhibiting molecules we focused on peptide-nucleic acids (PNAs). As miRNA to be targeted, miR-15b-5p was selected on the basis of several information present in the literature and confirming that miR-15b-5p is overexpressed in colon cancer patients, and that its targeting decreases cell migration and metastasis in colorectal cancer. In this article, we described for the first time the efficacy of targeting miR-15b-5p by using a PNA against miR-15b-5p (R8-PNA-a15b), functionalized with an octoarginine peptide (R8) for maximizing cellular uptake. The miR-15b-5p downregulation in the colon cancer HT-29 cell line was associated with inhibition of in vitro cell growth and activation of the proapoptotic pathway, demonstrated by a sharp increase of late apoptotic cells in HT-29-treated cell populations. A second conclusion of this study is that the R8-PNA-a15b might be proposed in “combo-therapy” associated with SFN. To our knowledge, no report is available in the literature on a combination between SFN and miRNA-targeting molecules. Our data demonstrate that this combined treatment leads to a very high proportion of apoptotic HT-29 cells (over 85%), a value higher than the sum of the values of apoptotic cells obtained after singularly administered regents (either SFN or R8-PNA-a15b).
Get full access to this article
View all access options for this article.
References
1.
ConzattiA, FróesFC, Schweigert PerryID and SouzaCG. (2014). Clinical and molecular evidence of the consumption of broccoli, glucoraphanin and sulforaphane in humans. Nutr Hosp, 31:559–569.
2.
LattéKP, AppelKE and LampenA. (2011). Health benefits and possible risks of broccoli—an overview. Food Chem Toxicol, 49:3287–3309.
3.
BachiegaP, SalgadoJM, de CarvalhoJE, ARuizLTG, SchwarzK, TezottoT and MorzelleMC. (2016). Antioxidant and antiproliferative activities in different maturation stages of broccoli (Brassica oleracea Italica) biofortified with selenium. Food Chem, 190:771–776.
4.
SturmC and Wagner.AE (2017). Brassica-derived plant bioactives as modulators of chemopreventive and inflammatory signaling pathways. Int J Mol Sci, 18:E1890.
5.
HerrI and BüchlerMW. (2010). Dietary constituents of broccoli and other cruciferous vegetables: implications for prevention and therapy of cancer. Cancer Treat Rev, 36:377–383.
6.
TseG and EslickGD. (2014). Cruciferous vegetables and risk of colorectal neoplasms: a systematic review and meta-analysis. Nutr Cancer, 66:128–139.
7.
LangnerE, LemieszekMK and Rzeski.W (2019). Lycopene, sulforaphane, quercetin, and curcumin applied together show improved antiproliferative potential in colon cancer cells in vitro. J Food Biochem, 43:e12802.
8.
TafakhMS, SaidijamM, RanjbarnejadT, MalihS, MirzamohammadiS and NajafiR. (2018). Sulforaphane, a chemopreventive compound, inhibits cyclooxygenase-2 and microsomal prostaglandin e synthase-1 expression in human HT-29 colon cancer cells. Cells Tissues Organs, 206:46–53.
9.
BesslerH and DjaldettiM. (2018). Broccoli and human health: immunomodulatory effect of sulforaphane in a model of colon cancer. Int J Food Sci Nutr, 69:946–953.
10.
MartinSL, KalaR and TollefsbolTO. (2018). Mechanisms for the inhibition of colon cancer cells by sulforaphane through epigenetic modulation of microRNA-21 and human telomerase reverse transcriptase (hTERT) down-regulation. Curr Cancer Drug Targets, 18:97–106.
11.
LiuKC, ShihTY, KuoCL, MaYS, YangJL, WuPP, HuangYP, LaiKC and ChungJG. (2016). Sulforaphane induces cell death through G2/M phase arrest and triggers apoptosis in HCT 116 human colon cancer cells. Am J Chin Med, 44:1289–1310.
12.
FabbriM, IvanM, CimminoA, NegriniM and CalinGA. (2007). Regulatory mechanisms of microRNAs involvement in cancer. Expert Opin Biol Ther, 7:1009–1019.
13.
AnvarniaA, Mohaddes-GharamalekiF, AsadiM, AkbariM, YousefiB and ShanehbandiD. (2019). Dysregulated microRNAs in colorectal carcinogenesis: new insight to cell survival and apoptosis regulation. J Cell Physiol, 234:21683–21693.
14.
SoleimaniA, RahmaniF, FernsGA, RyzhikovM, AvanA and HassanianSM. (2018). Role of regulatory oncogenic or tumor suppressor miRNAs of PI3K/AKT signaling axis in the pathogenesis of colorectal cancer. Curr Pharm Des, 24:4605–4610.
15.
AsadzadehZ, MansooriB, MohammadiA, AghajaniM, Haji-AsgarzadehK, SafarzadehE, MokhtarzadehA, DuijfPHG and BaradaranB. (2018). microRNAs in cancer stem cells: biology, pathways, and therapeutic opportunities. J Cell Physiol, 234:10002–10017.
16.
MollaeiH, SafaralizadehR and RostamiZ. (2019). MicroRNA replacement therapy in cancer. J Cell Physiol, 234:12369–12384.
17.
ZhangL, LiaoY and Tang.L (2019). MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. J Exp Clin Cancer Res, 38:53.
18.
GambariR, BrognaraE, SpandidosDA and FabbriE. (2016). Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: new trends in the development of miRNA therapeutic strategies in oncology (review). Int J Oncol, 49:5–32.
19.
ZhangL, HeL, ZhangH and ChenY. (2018). Knockdown of MiR-20a enhances sensitivity of colorectal cancer cells to cisplatin by increasing ASK1 expression. Cell Physiol Biochem, 47:1432–1441.
20.
BertucciA, PrasetyantoEA, SeptiadiD, ManicardiA, BrognaraE, GambariR, CorradiniR and De ColaL. (2015). Combined delivery of temozolomide and anti-miR221 PNA using mesoporous silica nanoparticles induces apoptosis in resistant glioma cells. Small, 11:5687–5695.
21.
MiroshnichenkoS and Patutina.O (2019). Enhanced inhibition of tumorigenesis using combinations of miRNA-targeted therapeutics. Front Pharmacol, 10:488.
22.
FabbriE, ManicardiA, TedeschiT, SforzaS, BianchiN, BrognaraE, FinottiA, BreveglieriG, BorgattiM, et al. (2011). Modulation of the biological activity of microRNA-210 with peptide nucleic acids (PNAs). ChemMedChem, 6:2192–2202.
23.
BrognaraE, FabbriE, BazzoliE, MontagnerG, GhimentonC, EccherA, CantùC, ManicardiA, BianchiN, et al. (2014). Uptake by human glioma cell lines and biological effects of a peptide-nucleic acids targeting miR-221. J Neurooncol, 118:19–28.
24.
BeaversKR, WerfelTA, ShenT, KavanaughTE, KilchristKV, MaresJW, FainJS, WieseCB, VickersKC, WeissSM and DuvallCL. (2016). Porous silicon and polymer nanocomposites for delivery of peptide nucleic acids as anti-MicroRNA therapies. Adv Mater, 28:7984–7992.
25.
GuptaA, QuijanoE, LiuY, BahalR, ScanlonSE, SongE, HsiehWC, BraddockDE, LyDH, SaltzmanWM and GlazerPM. (2017). Anti-tumor activity of miniPEG-γ-modified PNAs to inhibit microRNA-210 for cancer therapy. Mol Ther Nucleic Acids, 9:111–119.
26.
ManicardiA, GambariR, de ColaL and CorradiniR. (2018). Preparation of anti-miR PNAs for drug development and nanomedicine. Methods Mol Biol, 1811:49–63.
27.
SeoYE, SuhHW, BahalR, JosowitzA, ZhangJ, SongE, CuiJ, NoorbakhshS, JacksonC, et al. (2019). Nanoparticle-mediated intratumoral inhibition of miR-21 for improved survival in glioblastoma. Biomaterials, 201:87–98.
28.
MilaniR, BrognaraE, FabbriE, ManicardiA, CorradiniR, FinottiA, GasparelloJ, BorgattiM, CosenzaLC, et al. (2019). Targeting miR-155-5p and miR-221-3p by peptide nucleic acids induces caspase-3 activation and apoptosis in temozolomide-resistant T98G glioma cells. Int J Oncol, 55:59–68.
29.
XiY, FormentiniA, ChienM, WeirDB, RussoJJ, JuJ, KornmannM and JuJ. (2006). Prognostic values of microRNAs in colorectal cancer. Biomark Insights, 2:113–121.
30.
YangJ, MaD, FeslerA, ZhaiH, LeamniramitA, LiW, WuS and JuJ. (2016). Expression analysis of microRNA as prognostic biomarkers in colorectal cancer. Oncotarget, 8:52403–52412.
31.
PanC, YanX, LiH, HuangL, YinM, YangY, GaoR, HongL, MaY, et al. (2017). Systematic literature review and clinical validation of circulating microRNAs as diagnostic biomarkers for colorectal cancer. Oncotarget, 8:68317–68328.
32.
LiJ, ChenY, GuoX, ZhouL, JiaZ, TangY, LinL, LiuW and RenC. (2016). Inhibition of miR-15b decreases cell migration and metastasis in colorectal cancer. Tumour Biol, 37:8765–8773.
33.
SunLN, ZhiZ, ChenLY, ZhouQ, LiXM, GanWJ, ChenS, YangM, LiuY, et al. (2017). SIRT1 suppresses colorectal cancer metastasis by transcriptional repression of miR-15b-5p. Cancer Lett, 409:104–115.
34.
PanWY, ZengJH, WenDY, WangJY, WangPP, ChenG and FengZB. (2019). Oncogenic value of microRNA-15b-5p in hepatocellular carcinoma and a bioinformatics investigation. Oncol Lett, 17:1695–1713.
35.
ChenR, ShengL, ZhangHJ, JiM and QianWQ. (2018). miR-15b-5p facilitates the tumorigenicity by targeting RECK and predicts tumour recurrence in prostate cancer. J Cell Mol Med, 22:1855–1863.
36.
WangF, ZuY, ZhuS, YangY, HuangW, XieH and LiG. (2018). Long noncoding RNA MAGI2-AS3 regulates CCDC19 expression by sponging miR-15b-5p and suppresses bladder cancer progression. Biochem Biophys Res Commun, 507:231–235.
37.
NielsenPE, EgholmM, BergRH, and BuchardtO. (1991). Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science, 254:1497–1500.
38.
Nielsen PE. (2001). Targeting double stranded DNA with peptide nucleic acid (PNA). Curr Med Chem, 8:545–550.
39.
BorgattiM, LamprontiI, RomanelliA, PedoneC, SavianoM, BianchiN, MischiatiC and GambariR. (2003). Transcription factor decoy molecules based on a peptide nucleic acid (PNA)-DNA chimera mimicking Sp1 binding sites. J Biol Chem, 278:7500–7509.
40.
GambariR. (2001). Peptide-nucleic acids (PNAs): a tool for the development of gene expression modifiers. Curr Pharm Des, 7:1839–1862.
41.
GambariR. (2004). Biological activity and delivery of peptide nucleic acids (PNA)-DNA chimeras for transcription factor decoy (TFD) pharmacotherapy. Curr Med Chem, 11:1253–1263.
42.
Nielsen PE. (2010). Peptide nucleic acids (PNA) in chemical biology and drug discovery. Chem Biodivers, 7:786–804.
43.
Nielsen PE. (2010). Gene targeting and expression modulation by peptide nucleic acids (PNA). Curr Pharm Des, 16:3118–3123.
44.
QuijanoE, BahalR, RicciardiA, SaltzmanWM and GlazerPM. (2017). Therapeutic peptide nucleic acids: principles, limitations, and opportunities. Yale J Biol Med, 90:583–598.
45.
ShirafkanN, ShomaliN, KazemiT, ShanehbandiD, GhasabiM, BaghbaniE, GanjiM, KhazeV, MansooriB and Baradaran.B (2018). microRNA-193a-5p inhibits migration of human HT-29 colon cancer cells via suppression of metastasis pathway. J Cell Biochem [Epub ahead of print]. DOI: 10.1002/jcb.28164.
46.
GasparelloJ, AllegrettiM, TremanteE, FabbriE, AmoreoCA, RomaniaP, MelucciE, MessanaK, BorgattiM, et al. (2018). Liquid biopsy in mice bearing colorectal carcinoma xenografts: gateways regulating the levels of circulating tumor DNA (ctDNA) and miRNA (ctmiRNA). J Exp Clin Cancer Res, 37:124.
47.
ChouTC and TalalayP. (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul, 22:27–55.
48.
Chou TC. (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev, 68:621–681.
49.
Chou TC. (2010). Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res, 70:440–446.
50.
ZhangN, FuJN, and ChouTC. (2016). Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method. Am J Cancer Res. 6:97–104.
51.
ErJL, GohPN, LeeCY, TanYJ, HiiLW, MaiCW, ChungFF and LeongCO. (2018). Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC). Apoptosis, 23:343–355.
52.
LowSY, TanBS, ChooHL, TiongKH, KhooAS and LeongCO. (2012). Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells. Cancer Lett, 314:166–175.
53.
WongSW, TiongKH, KongWY, YueYC, ChuaCH, LimJY, LeeCY, QuahSI, FowC, et al. (2011). Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through upregulation of p73. Breast Cancer Res Treat, 128:301–313.
54.
ChughA, EudesF, and ShimYS. (2010). Cell-penetrating peptides: nanocarrier for macromolecule delivery in living cells. IUBMB Life, 62:183–193.
55.
FinottiA, GasparelloJ, FabbriE, TamaniniA, CorradiniR, DechecchiMC, CabriniG and GambariR. (2019). Enhancing the expression of CFTR using antisense molecules against microRNA miR-145-5p. Am J Respir Crit Care Med, 199:1443–1444.
56.
PorterAG and JänickeRU. (1999). Emerging roles of caspase-3 in apoptosis. Cell Death Differ, 6:99–104.
57.
AubreyBJ, KellyGL, JanicA, HeroldMJ and StrasserA. (2018). How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ, 25:104–113.
58.
LindqvistLM and VauxDL. (2014). BCL2 and related prosurvival proteins require BAK1 and BAX to affect autophagy. Autophagy, 10:1474–1475
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
